Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human. biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II.
View Top Employees from KynexisWebsite | https://www.kynexistx.com |
Employees | 18 (8 on RocketReach) |
Industry | Biotechnology Research |
Looking for a particular Kynexis employee's phone or email?
Jens Wendland is the Chief Medical Officer of Kynexis.
8 people are employed at Kynexis.